Donate
Families and researchers are counting on you !

Latest news

Find here all the latest news on AFM-Telethon and rare diseases.

Discover the latest news

(optional)
best-of research
Research
23/01/2023

Protagonists of a medical revolution, researchers testify 

Their determination and expertise are at the origin of great scientific advances and major victories. Thanks to the researchers in the Telethon laboratories, children suffering from formerly incurable diseases have been saved. 

voeux-vignetteok
Event
05/01/2023

Best wishes for 2023 !

The AFM-Telethon sends you its best wishes for the New Year and wishes you a year 2023 full of color and joy!

Téléthon 2022 merci
Telethon
09/12/2022

Téléthon 2022 : € 78 051 091. Thank you very much! 

The Téléthon 30-hour-long broadcast ended with donations totaling 78 051 091 euros. From Guebwiller to Cassis, Dijon, Lorient and Cap-Ferret, millions of people came together again for the Téléthon, this unique celebration with its thousands of events. A vital support for the families and researchers, “these saving lives maniacs” as Kev Adams called them. But while researchers’ victories multiply, all week-end long patients and their families reminded everyone of the urgency of finding new treatments. 

document advance in research
Research
07/12/2022

Advances in research: a new document is available

"Advances in Charcot-Marie-Tooth (CMT) disease" is a new document, published by the French Muscular Dystrophy Association (AFM-Téléthon), which can be read and/or downloaded here.

TFE 2022
Telethon
04/11/2022

December 2 and 3: ready for the Telethon!

You live abroad and want to play a part in the Telethon? Join the Telethon for French people abroad and help us break records of mobilization around the world! 

Myology 2022 congress
Research
19/09/2022

A look back at Myology 2022 

During four days, from 12 to 15th of September, researchers, clinicians and myology experts have attended the seventh International Congress of Myology, organized by AFM-Téléthon, in Nice, France. A good opportunity to exchange and share knowledge about myology and innovative therapies. Let’s have a look back at Myology 2022 with our researchers’ video interviews.

Myology2022-ptogramme
Event
25/08/2022

Myology 2022 and MitoNice 2022: the program is available!

From September 12 to 17th, AFM-Telethon will hold two successive scientific congresses gathering close to 1000 international experts on myology and mitochondrial medicine at the Nice Acropolis Convention Centre. Registrations are open!

Soprano-Parrain-2021
Telethon
28/04/2022

Telethon 2021: What an unbelievable result! 

Through the collective mobilization of donors, volunteers, families, and partners, all united in solidarity to fight against rare diseases, the final result of the 2021 Telethon amounts to €85.933.166. Thank you!

AFM-Telethon-Telethon-TV-program: Since 1987, the Telethon is a TV marathon lasting around thirty hours and broadcast on the France Télévisions TV channels.
Telethon
06/12/2021

€ 73 622 019 thank you! The fight can continue!

The 2021 Telethon ended with donations totaling 73 622 019 euros. An amount reflecting the generosity of the general public, the energy felt during thousands of Telethon events throughout France and abroad, and the strength of families’ fight and researchers’ determination. This unique combination is the cause for a true revolution in medicine that saves lives and opens up new prospects for treatment.

Téléthon 2018 Victoire Crigler-Najjar
Research
02/07/2021

Preliminary results of clinical trial for rare liver disease Crigler-Najjar syndrome presented at EASL congress

Preliminary results from the European gene therapy trial for Crigler-Najjar syndrome, conducted by Généthon in collaboration with European network CureCN, were presented at the EASL (European Association for the Study of the Liver) annual International Liver Congress on June 26. Based on initial observations, the drug candidate is well tolerated and the first therapeutic effects have been demonstrated, to be confirmed as the trial continues.